We are live on ! Find out more
GRCE

Grace Therapeutics
GRCE

34 hedge funds and large institutions have $19.7M invested in Grace Therapeutics in 2026 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

260% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 5

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

48% more funds holding

Funds holding: 23 → 34 (+11)

32% more capital invested

Capital invested by funds: $15M → $19.7M (+$4.75M)

4% more call options, than puts

Call options by funds: $326K | Put options by funds: $314K

0.41% less ownership

Funds ownership: 27.97% → 27.56% (-0.41%)

Holders
34
Holders Change
+11
Holders Change %
+47.83%
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
6
Reduced
4
Closed
5
Calls
$326K
Puts
$314K
Net Calls
+$12K
Net Calls Change
+$12K

Top Buyers

Rank Fund Capital Flow
1
EP
Eversept Partners
New York
+$2.97M
2
Cerity Partners
Cerity Partners
New York
+$1.67M
3
Jane Street
Jane Street
New York
+$656K
4
Renaissance Technologies
Renaissance Technologies
New York
+$448K
5
Marshall Wace
Marshall Wace
United Kingdom
+$359K

Top Sellers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
-$3.15M
2
ACM
ADAR1 Capital Management
Texas
-$2.22M
3
NCM
Nantahala Capital Management
Connecticut
-$1.77M
4
Morgan Stanley
Morgan Stanley
New York
-$82.1K
5
GCP
GSA Capital Partners
United Kingdom
-$48K
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
26
Royal Bank of Canada
Ontario, Canada
$3K – – –
AAP
27
Arax Advisory Partners
Colorado
$2.31K +$1.96K +500 New
TRCT
28
Tower Research Capital (TRC)
New York
$1.92K -$6.01K -1,530 -79%
AWM
29
Activest Wealth Management
Florida
$482 – – –
CIAM
30
Caitong International Asset Management
Hong Kong
$380 +$322 +82 New
SS
31
SBI Securities
Japan
$324 -$122 -31 -31%
SPIA
32
Steward Partners Investment Advisory
New York
$190 – – –
NS
33
NBC Securities
Alabama
$9 – – –
FDCDDQ
34
Federation des caisses Desjardins du Quebec
Quebec, Canada
$5 – – –
ACM
35
AIGH Capital Management
Maryland
– -$3.15M -907,217 Closed
ACM
36
ADAR1 Capital Management
Texas
– -$2.22M -641,988 Closed
GCP
37
GSA Capital Partners
United Kingdom
– -$48K -13,774 Closed
SWP
38
Stratos Wealth Partners
Ohio
– -$38.7K -11,182 Closed
FHA
39
Flagship Harbor Advisors
Massachusetts
– -$7 -2 Closed
1
2

GRCE Hedge Fund Activity: Q1 2026 in Review

34 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q1 2026, worth a combined $19.7M — up 32% from $15M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new GRCE positions and 5 closed out — a net gain of 13 holders — while 6 added to existing stakes and 4 trimmed.

The largest buyer was Eversept Partners, opening a new position worth an estimated $2.97M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $3.15M sold.

  • 34 institutional investors held Grace Therapeutics (GRCE) as of Q1 2026, up from 23 in Q4 2025.
  • Funds reported $19.7M of Grace Therapeutics stock for Q1 2026, up 32% quarter-over-quarter.
  • 18 funds opened new Grace Therapeutics positions in Q1 2026 and 5 closed out, a net change of +13 holders.
  • The largest Grace Therapeutics buyer in Q1 2026 was Eversept Partners, an estimated $2.97M added.
  • The largest Grace Therapeutics seller in Q1 2026 was AIGH Capital Management, an estimated $3.15M sold.

Based on aggregated 13F filings for Q1 2026.